Vinorelbine Plus Fluorouracil in Treating Women With Metastatic Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed metastatic breast cancer
• At least 1 line of prior chemotherapy for metastatic disease (adjuvant or neoadjuvant chemotherapy is considered first line if completed less than one year prior to palliative chemotherapy)
• No cerebral metastases
• Hormonal receptor status:
• * Not specified
• PATIENT CHARACTERISTICS:
• Age:
• Not specified
• Sex:
• Female
• Menopausal status:
• Not specified
• Performance status:
• WHO 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm \^3
• Hepatic:
• Bilirubin no greater than 2.5 times upper limit of normal (ULN)
• AST/ALT no greater than 2.5 times ULN
• Renal:
• Creatinine no greater than 1.58 mg/dL
• Cardiovascular:
• No clinically significant cardiac insufficiency or ischemic disease
• Pulmonary:
• No bronchoconstriction other than pulmonary lymphangitis
• Other:
• No serious chronic disease
• No bowel obstruction
• Not pregnant or nursing
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No concurrent immunotherapy
• No concurrent prophylactic growth factor
• Chemotherapy:
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy
• No prior high-dose chemotherapy
• No other concurrent chemotherapy
• Endocrine therapy:
• No concurrent hormonal therapy
• No concurrent steroid therapy except in an emergency
• Radiotherapy:
• At least 4 weeks since prior radiotherapy (for primary tumor or axillary or mammary chain treatment only)
• No concurrent radiotherapy
• Surgery:
• Not specified
• Other:
• No other concurrent antitumor therapy